Table 3 Transition probabilities and utilities used in the analysis.

From: Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma

 

Value

Lower limit

Higher limit

Probabilities

ECX group

 PPFS-PFS

0.81

0.56

1.00

 PPFS-PD

0.12

0.09

0.16

 PPFS-death

0.07

0.05

0.09

 PPD-PD

0.85

0.59

1.00

 PPD-death

0.15

0.11

0.20

FOLFIRI group

 PPFS-PFS

0.82

0.57

1.00

 PPFS-PD

0.11

0.08

0.15

 PPFS-death

0.07

0.05

0.09

 PPD-PD

0.83

0.58

1.00

 PPD-death

0.17

0.12

0.22

Utility

 PFS state

0.80

0.56

1.00

 PD state

0.60

0.42

0.78

 Death state

0.00

0.00

0.00

  1. P: transition probability; PFS, progression-free survival; PD, progressive disease; ECX, epirubicin, cisplatin, and capecitabine; FOLFIRI, fluorouracil, leucovorin, and irinotecan.
Back to article page